Skip to main content
Premium Trial:

Request an Annual Quote

Roche Applied Science, AgenoLab, Promega, Leica

Premium
Roche Signs AgenoLab as First Customer for xCelligence Cell Analysis System
 
Roche Applied Science said this week that biotech services company AgenoLab has installed the xCelligence System, which Roche distributes through a partnership with Acea Biosciences.
 
Roche said Stuttgart, Germany-based AgenoLab purchased the xCelligence in April and installed it in July, making it the first customer to purchase the cell-based assay platform.
 
AgenoLab performs services in microbiology, molecular biology, cell culture technology, tissue engineering, and in other biomedical areas.
 
The system was originally developed by the San Diego-based Acea and was further developed with Roche as part of a marketing agreement the companies signed in November 2007 (see CBA News, 11/16/07).
 
Roche holds exclusive worldwide marketing rights to the technology.
 
The xCelligence platform is a label-free system that monitors cellular events in real time. It uses electrical impedance measurement to provide information about cell number, viability, and morphology.
 
Financial terms of the agreement with AgenoLab were not released.
 

 
Promega, Leica to Develop Fluorescent Proteins for Live-Cell Imaging
 
Promega said this week that it has signed an agreement with Leica Microsystems to develop fluorescent labels for proteins so that they can be visualized in live cells using a Leica super-resolution microscope.
 
Promega said it will develop fluorescent ligands for its HaloTag fusion proteins, which will be visualized within live cells using Leica’s TCS stimulated emission depletion, or STED, microscope.
 
Current fluorescent imaging methods, such as green fluorescent protein, are generally not optimal for use with STED technology, the company said, because they “are prone to photobleaching and lack appropriate spectral properties,” while other protein-labeling methods, such as fluorescent antibodies, are only applicable to fixed cells.
 
Promega said that the agreement with Leica will enable the imaging of proteins within live cells below the 100-nanometer range.
 

It added that it has been working with the imaging company since 2006 to develop novel ways to label proteins within cells.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.